Investigational drug · Phase 2
DFV890
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Coronary Heart Disease, Symptomatic Knee Osteoarthritis.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
6
Any phase or sponsor naming "DFV890"
First trial start
2021
Sep 20, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DFV890", any sponsor or status.
Conditions studied
As listed on its trial records.
- Coronary Heart Disease
- Symptomatic Knee Osteoarthritis
Approved drugs for the same conditions: Osteoarthritis · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "DFV890" as an intervention, largest first.
- Study of Efficacy and Safety of DV890 in Patients With COVID-19 PneumoniaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04382053 · 143 participants · Start May 27, 2020 · Primary completion Dec 10, 2020
Drug: DFV890; Standard of Care (SoC) · For: COVID-19 Pneumonia, Impaired Respiratory Function
Sites: CABA, Argentina; Buenos Aires, Argentina; Porto Alegre, Brazil · 29 sites in all
- Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee OsteoarthritisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04886258 · 115 participants · Start Sep 20, 2021 · Primary completion Dec 14, 2024
Drug: DFV890; Placebo · For: Symptomatic Knee Osteoarthritis
Sites: Phoenix, Arizona; El Cajon, California; Colorado Springs, Colorado · 31 sites in all
- Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid DiseasesActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05552469 · 71 participants · Start May 8, 2023 · Primary completion Feb 1, 2027
Drug: DFV890 · For: Myeloid Diseases
Sites: Stanford, California; Tampa, Florida; Chicago, Illinois · 25 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT06097663 · 31 participants · Start Feb 15, 2024 · Primary completion Oct 27, 2024
Drug: MAS825; MAS825 Placebo and 2 more · For: Coronary Heart Disease; Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Sites: St Louis, Missouri; Nashville, Tennessee; Montreal, Canada · 6 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT06031844 · 24 participants · Start Oct 16, 2023 · Primary completion Dec 17, 2024
Drug: DFV890; DFV890 Placebo · For: Coronary Heart Disease
Sites: Northridge, California; Boca Raton, Florida; Jacksonville, Florida · 7 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04868968 · 4 participants · Start Sep 20, 2021 · Primary completion Dec 13, 2022
Drug: DFV890 · For: Familial Cold Autoinflammatory Syndrome
Sites: La Jolla, California; Paris, France; Tübingen, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Immunopharmacological reprogramming of innate immune memory in Alzheimer's disease: From microglial priming to therapeutic resilience.
Abdelaziz AM, Eladawy RM · Biochem Pharmacol 2026
- Correction to "Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor".
Shen DM, Byth KF, Bertheloot D, et al. · J Med Chem 2025
- Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor.
Shen DM, Byth KF, Bertheloot D, et al. · J Med Chem 2025
- First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor.
Gatlik E, Mehes B, Voltz E, et al. · Clin Transl Sci 2024
- Research progress of NLRP3 inflammasome and its inhibitors with aging diseases.
Yuan Z, Yu D, Gou T, et al. · Eur J Pharmacol 2023
- DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.
Madurka I, Vishnevsky A, Soriano JB, et al. · Infection 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.